Atlas Trials

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies

Clinical trial NCT02504346 · UNKNOWN

Trial details

NCT number
NCT02504346
Sponsor
Oslo University Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Lung CancerTargeted Therapy
Start date
2015-08-01
Primary completion
2023-06-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.